Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.40 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 2/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14569262 | 1.00 | LMNA (0.60) | LMNAAOC3MEN1KMT2AKDM4E | |
| SCHEMBL1978021 | 1.00 | LMNA (0.60) | LMNAAOC3MEN1KMT2AKDM4E | |
| SCHEMBL8537264 | 0.90 | LMNA (0.50) | LMNAAOC3MEN1KMT2AKDM4E | |
| SCHEMBL1607138 | 0.87 | LMNA (0.75) | LMNAAOC3KDM4EPGRALDH1A1 | |
| SCHEMBL13262326 | 0.82 | AOC3 (0.53) | AOC3MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL906150 | 0.82 | AOC3 (0.53) | AOC3MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL13969826 | 0.81 | AOC3 (0.52) | LMNAAOC3MEN1KMT2AKDM4E | |
| SCHEMBL18290601 | 0.81 | LMNA (0.60) | LMNAAOC3KDM4EPGRALDH1A1 | |
| SCHEMBL18503058 | 0.80 | AOC3 (0.52) | AOC3MEN1KMT2AKDM4EHTR7 | |
| SCHEMBL29861210 | 0.80 | LMNA (0.65) | LMNAAOC3KDM4EPGRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663508-B2 | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663508-B2 | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | One Amgen Center Drive (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | One Amgen Center Drive (US) | 2016-07-28 | — | — | US | disclosed |
| EP-2229938-B9 | Ezetimibe compositions | SANOVEL ILAC SANAYI VE TICARET AS (TR) | 2012-04-25 | — | — | EP | disclosed |
| EP-2266623-A2 | Prodrugs containing novel bio-cleavable linkers | Piramal Life Sciences Limited (IN) | 2010-12-29 | — | — | EP | disclosed |
| WO-2008106900-A1 | METHOD OF MANUFACTURING (3R, 4S) -1- (4-FLUOROPHENYL) -3- [ (3S) -3- (4 -FLUOROPHENYL) -3-HYDROXYPROPYL) ] -4- (4-HYD ROXYPHENYL) -2-AZETIDINONE | ZENTIVA, A.S. (CZ) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008057948-A2 | PROCESSES FOR PRODUCTION OF DIPHENYLYLAZETIDIN-2-ONES AND RELATED COMPOUNDS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2007119106-A2 | PROCESSES FOR PREPARING INTERMEDIATE COMPOUNDS USEFUL FOR THE PREPARATION OF EZETIMIBE | MEDICHEM, S.A. (US) | 2007-10-25 | — | — | WO | disclosed |
| EP-1593670-B1 | Hydroxy-substituted 2-azetidinones useful as hypocholesterolemic agents | SCHERING CORP (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2007044318-A2 | ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS | MERCK & CO., INC. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | SCN1A, SCN1B, SCN5A | LMNA 1834/4885AOC3 3999/4885MEN1 3534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.